1. Introduction {#sec0005}
===============

Porcine deltacoronavirus (PDCoV), an emerging swine enteric coronavirus (CoV), belongs to the newly identified genus *Deltacoronavirus*, family *Coronaviridae* in the order *Nidovirales* ([@bib0115]; [@bib0195]). Clinically, PDCoV infection causes severe diarrhea and intestinal pathological damage in nursing piglets ([@bib0080]; [@bib0180]; [@bib0215]). PDCoV was first identified in 2012 during molecular surveillance of CoVs in mammals and birds in Hong Kong ([@bib0205]). In 2014, outbreaks of PDCoV were reported in some states of the United States ([@bib0010]; [@bib0060]; [@bib0120]; [@bib0190]). Thereafter, PDCoV was also detected in farmed pigs with diarrhea in other countries, including South Korea ([@bib0075]; [@bib0095]), China ([@bib0035]; [@bib0160]; [@bib0175]), Thailand ([@bib0070]), Japan ([@bib0170]), Laos, and Vietnam ([@bib0105]; [@bib0140]), causing great economic losses in the swine industry. Recently, Jung and co-workers reported that calves are also susceptible to infection with PDCoV ([@bib0085]), sparking an increased interest in studying this emerging virus.

PDCoV is single-stranded, positive-sense RNA virus with an envelope, and its full-length genome, approximately 25.4 kb, is the smallest genome among the known CoVs ([@bib0115]; [@bib0205]). The typical genome of PDCoV successively contains 5ʹUTR-ORF1a-ORF1b-S-E-M-NS6-N-NS7-NS7a-3ʹUTR, which encodes two viral replicase polyproteins that are predicted to be proteolytically processed to yield 15 replication- and transcription-associated mature nonstructural proteins (nsps), four structural proteins, and three accessory proteins ([@bib0040], [@bib0045]; [@bib0205]). Based on studies of other known CoVs, the proteases from PDCoV nsps that are required for viral replication and transcription have been predicted, such as papain-like protease nsp3, 3C-like protease nsp5, RNA-binding protein nsp9, RNA-dependent RNA polymerase nsp12, helicase nsp13, and endoribonuclease nsp15 ([@bib0125]; [@bib0245]; [@bib0235], [@bib0240]). Of these, the endoribonuclease, termed NendoU, is highly conserved among vertebrate nidoviruses (coronaviruses and arteriviruses) but is not conserved among other RNA viruses, making it a genetic marker of this virus order ([@bib0065]; [@bib0155]). NendoU, reported to have similarities to XendoU, specifically cleaves RNA at the level of 5ʹ uridines to release a 2ʹ-3ʹ-cyclic phosphate end product in the presence of Mn^2+^, which is considered to be an integral component of the replicase-transcriptase complex of nidoviruses and plays a critical role in viral replication and transcription ([@bib0005]; [@bib0130]).

Besides their roles in viral replication and transcription, the nsp15 of some CoVs and its orthologue nsp11 in arteriviruses have been demonstrated to antagonize innate immune responses. Overexpression of severe acute respiratory syndrome coronavirus (SARS-CoV) nsp15 significantly inhibits type I interferon (IFN) production, and the possible mechanism is via inhibiting MAVS-induced apoptosis ([@bib0055]; [@bib0100]). However, this mechanism appears not to be shared by other CoVs ([@bib0100]). Porcine epidemic diarrhea virus (PEDV) nsp15 has been shown to suppress poly(I:C)-induced type I and type III IFN responses and the endoribonuclease activity appears to be not required for PEDV replication in IFN-deficient Vero cells ([@bib0225]; [@bib0025]). A recombinant mouse hepatitis virus (MHV) strain A59 with a mutation in the active site of endoribonuclease nsp15 can stimulate an early and robust induction of type I IFN in macrophages by activating host double-stranded RNA (dsRNA) sensors, indicating that MHV A59 nsp15 may function as an IFN antagonist during MHV infection ([@bib0020]). Several studies have demonstrated that arterivirus nsp11 s inhibit innate immune responses and their endoribonuclease activity is required ([@bib0145]; [@bib0165]). Additionally, our previous studies showed that PDCoV infection suppresses RIG-I-mediated production of IFN-β ([@bib0110]). However, whether or not PDCoV nsp15 is also a type I IFN antagonist remains unclear.

In the present study, we demonstrated that PDCoV nsp15 also inhibits IFN-β production by impairing nuclear factor-κB (NF-κB) activation. Furthermore, we found that the endoribonuclease activity of PDCoV nsp15 is not essential for its ability to antagonize IFN-β production.

2. Materials and methods {#sec0010}
========================

2.1. Cells, viruses, and reagents {#sec0015}
---------------------------------

LLC-PK1 cells (porcine kidney cells) were purchased from the ATCC (ATCC CL-101) and cultured in Dulbecco\'s modified Eagle\'s medium (Invitrogen, USA) supplemented with 10% fetal bovine serum at 37 °C in a humidified 5% CO~2~ incubator. HEK-293T cells, obtained from the China Center for Type Culture Collection (CCTCC), were cultured in Dulbecco\'s modified Eagle\'s medium (Invitrogen, USA) supplemented with 10% fetal bovine serum under the same conditions described above. PDCoV strain CHN-HN-2014 (GenBank accession number KT336560) was isolated from a piglet with acute diarrhea in China in 2014 ([@bib0030]). Sendai virus (SEV) was obtained from the Centre of Virus Resource and Information, Wuhan Institute of Virology, Chinese Academy of Sciences. Mouse monoclonal antibodies (MAbs) against hemagglutinin (HA) and β-actin were purchased from Medical and Biological Laboratories (Japan). Rabbit polyclonal antibodies directed against IRF3, phosphorylated IRF3 (p-IRF3), p65, and phosphorylated p65 (p-p65) were purchased from ABclonal (China) and Cell Signaling Technology.

2.2. Plasmids {#sec0020}
-------------

The luciferase reporter plasmids IFN-β-Luc, IRF3-Luc (4 × PRDIII/I-Luc), and NF-κB-Luc (4 × PRDII-Luc) were described previously ([@bib0185]). The nsp15 gene of PDCoV strain CHN-HN-2014 was amplified and used as the template for the mutagenesis of individual amino acid residues by overlap extension PCR using specific primers listed in [Table 1](#tbl0005){ref-type="table"} . The wild type (WT) nsp15 and its mutants (H219A, H234A, K269A) were cloned into pCAGGS-HA-C with a C-terminal HA tag to generate the eukaryotic expression constructs pCAGGS-HA-nsp15, pCAGGS-HA-H219A, pCAGGS-HA-H234A, and pCAGGS-HA-K269A. All constructs were verified by DNA sequencing.Table 1Primers used for the construction of plasmids and qPCR assays.Table 1PrimerNucleotide sequence (5^'^--3^'^)nsp15-FGCGGAATTCAACCTTGAAAACTTAGCTTACAACnsp15-RATACTCGAGCTGTAAGATTGGGTAGCAAGTCTTH219A-FGGTGTTGAAGCCATTATCTATGGTGATGATH219A-RATAGATAATGGCTTCAACACCCAGTTCCTGH234A-FGGCGGAACTGCCACACTTATCTCACTAGTTH234A-RGATAAGTGTGGCAGTTCCGCCAATGACTGGK269A-FTAACGCAAGCTCCGCGAACGTTTGCACTGTK269A-RGCAAACGTTCGCGGAGCTTGCGTTAGGTGAh-IFN-β-FTCTTTCCATGAGCTACAACTTGCTh-IFN-β-RGCAGTATTCAAGCCTCCCATTCh-GAPDH-FTCATGACCACAGTCCATGCCh-GAPDH-RGGATGACCTTGCCCACAGCCp-IFN-β-FGCTAACAAGTGCATCCTCCAAAp-IFN-β-RAGCACATCATAGCTCATGGAAAGAp-GAPDH-FACATGGCCTCCAAGGAGTAAGAp-GAPDH-RGATCGAGTTGGGGCTGTGACT

2.3. Luciferase reporter assay {#sec0025}
------------------------------

Monolayers of LLC-PK1 or HEK-293T cells grown in 24-well plates were transiently co-transfected with 0.1 μg of reporter plasmid (IFN-β-Luc, NK-κB-Luc, or IRF3-Luc) together with 0.02 μg of the internal control plasmid pRL-TK (Promega) and the indicated expression plasmids using Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions. At 24 h after transfection, cells were mock-infected or infected with SEV (10 hemagglutinating activity units/well) for 12 h. Finally, firefly and Renilla luciferase activities were determined with the Dual-Luciferase reporter assay system according to the manufacturer's protocol (Promega). Data are expressed as the luciferase activities of lysed cells, normalized to the activity of pRL-TK, and are representative of at least three independently conducted experiments. Data are presented as means ± standard deviations (SD).

2.4. RNA extraction and quantitative real-time PCR {#sec0030}
--------------------------------------------------

LLC-PK1 or HEK-293T cells in 24-well plates were transfected with 1 μg of empty vector or the indicated expression plasmid. After 24 h, the cells were left untreated or infected with SEV for 12 h. Total cellular RNA was extracted from the cells using TRIzol reagent (Invitrogen) and reverse transcribed into cDNA by avian myeloblastosis virus reverse transcriptase (TaKaRa, Japan). The above cDNA (1 μl of the 20 μl RT reaction mixture) were used as templates and subjected to SYBR green PCR assays (Applied Biosystems) at least three times. The IFN-β mRNA expression levels were normalized to the expression level of glyceraldehyde-3-phosphate dehydrogenase (GAPDH). The primers were designed with Primer Premier 5 software, and the sequences are listed in [Table 1](#tbl0005){ref-type="table"}.

2.5. Western blot analysis {#sec0035}
--------------------------

LLC-PK1 or HEK-293T cells were cultured in 60-mm dishes, transfected with the indicated plasmids for 24 h, and then infected or mock-infected with SEV (50 hemagglutinating activity units/dish) for 8 h. The cells were harvested by adding lysis buffer (4% SDS, 3% dithiothreitol \[DTT\], 0.065 mM Tris-HCl \[pH 6.8\], 30% glycerin) supplemented with a protease inhibitor cocktail, phenylmethylsulfonyl fluoride (PMSF), and a phosphatase inhibitor cocktail (Sigma). The samples were subjected to separation by 10% SDS-PAGE and transferred to polyvinylidene difluoride (PVDF) membranes (Millipore, USA) to determine protein expression. The endogenous expression of p-IRF3, p65, p-p65, and IRF3 proteins were analyzed with the indicated antibodies, anti-p-IRF3, anti-p65 (ABclonal), anti-p-p65, and anti-IRF3 (Cell Signaling Technology), respectively. The overexpression of a plasmid with a HA tag was evaluated with an anti-HA antibody (MBL), and the expression levels of β-actin were detected with an anti-β-actin monoclonal antibody (MBL). The detections of similar amounts among groups were taken to indicate equal protein sample loading.

2.6. Indirect immunofluorescence assay (IFA) {#sec0040}
--------------------------------------------

IFAs were performed to examine the subcellular localization of endogenous IRF3 and NF-κB subunit p65 in LLC-PK1 or HEK-293T cells. Cells seeded on microscope coverslips in 24-well plates were transfected with the indicated expression plasmid when the cells reached approximately 80% confluence. After 24 h, the cells were mock-infected or infected with SEV for 6 h. The cells were fixed with 4% paraformaldehyde for 15 min and then permeated with methyl alcohol for 10 min at room temperature. After three washes with PBST, the cells were sealed with PBST containing 5% bovine serum albumin (BSA) for 1 h, followed by incubation separately with a rabbit polyclonal antibody against IRF3 (1:200) or against p65 (1:200) or a mouse anti-HA antibody (1:200) for 1 h at room temperature. The cells were then treated with secondary antibodies Alexa Fluor 594-conjugated donkey anti-mouse IgG and Alexa Fluor 488-conjugated donkey anti-rabbit IgG (Santa Cruz Biotechnology) for 1 h at 37 °C, followed by treatment with 4ʹ, 6-diamidino-2-phenylindole (DAPI) (Beyotime, China) for 15 min at room temperature. After the samples were washed with PBST, fluorescent images were visualized and examined with a confocal laser scanning microscope (Fluoviewver. 3.1; Olympus, Japan).

2.7. IFN bioassay {#sec0045}
-----------------

To evaluate the effect of PDCoV nsp15 on the amount of IFN production by LLC-PK1 or HEK-293T cells following stimulation by SEV, IFN bioassays were performed as described previously ([@bib0050]).

2.8. Statistical analysis {#sec0050}
-------------------------

All experiments were performed in triplicate. Significant differences were determined using Student's *t*-tests, and *p* values of \<0.05 were considered statistically significant.

3. Results {#sec0055}
==========

3.1. PDCoV nsp15 inhibits SEV-induced IFN-β production {#sec0060}
------------------------------------------------------

To explore whether or not PDCoV nsp15 antagonizes IFN-β production, LLC-PK1 or HEK-293T cells were co-transfected with increasing amounts of a PDCoV nsp15 expression plasmid (pCAGGS-HA-nsp15) or an empty vector and the IFN-β-Luc reporter plasmid, along with pRL-TK (an internal control plasmid), and then infected with SEV for 12 h. The cell lysates were harvested, and the IFN-β promoter-driven luciferase activity and IFN-β mRNA expression levels were measured by dual-luciferase reporter assays and real-time RT-PCR analyses, respectively. As shown in [Fig. 1](#fig0005){ref-type="fig"} , ectopic expression of PDCoV nsp15 significantly inhibited SEV-induced IFN-β promoter activity in both LLC-PK1 ([Fig. 1](#fig0005){ref-type="fig"} **A**) and HEK-293T ([Fig. 1](#fig0005){ref-type="fig"} **C**) cells. The mRNA expression levels of IFN-β were also decreased compared with the control group in both cell lines ([Fig. 1](#fig0005){ref-type="fig"} **B** and **D**). To further verify the inhibition of IFN-β production on protein level by PDCoV nsp15, the IFN bioassay was performed by using an IFN-sensitive vesicular stomatitis virus expressing green fluorescent protein (VSV-GFP). As shown in [Fig. 1](#fig0005){ref-type="fig"} **E** and **F**, the cellular supernatants from SEV-infected LLC-PK1 and HEK-293T cells notably suppressed the replication of VSV-GFP in both cell lines. However, the replication of VSV-GFP was partially restored by the presence of supernatants from cells expressing PDCoV nsp15 compared to that of supernatants from empty vector-transfected cells. These results suggest that PDCoV nsp15 is an IFN-β antagonist.Fig. 1PDCoV nsp15 antagonizes SEV-induced IFN-β production. (**A**, **C**) LLC-PK1 cells (A) or HEK-293T cells (C) cultured in 24-well plates were co-transfected with IFN-β-Luc and pRL-TK together with increasing amounts (0.1, 0.5, and 1.0 μg) of pCAGGS-HA-nsp15 or empty vector. After 24 h, the cells were mock-infected or infected with SEV (10 hemagglutinating activity units/well) for 12 h and subjected to a dual-luciferase reporter assay. The relative firefly luciferase activity was normalized to the Renilla luciferase activity with the untreated empty vector control value set to 1. (**B**, **D**) LLC-PK1 cells (B) or HEK-293T cells (D) cultured in 24-well plates were co-transfected with 1.0 μg of pCAGGS-HA-nsp15 or empty vector for 24 h, and then left untreated or infected with SEV (10 hemagglutinating activity units/well). At 8 h after infection, the cells were collected, and total RNA was extracted to detect the expression levels of IFN-β and GAPDH by SYBR Green PCR assay. (**E**, **F**) LLC-PK1 (E) or HEK-293T (F) cells were transfected with 1.0 μg of pCAGGS-HA-nsp15 or empty vector. At 24 h after transfection, both cell lines were infected with SEV for 12 h and the cell supernatants were collected. The UV-irradiated cell supernatants were overlaid onto fresh LLC-PK1 or HEK-293T cells in 24-well plates. After 24 h of incubation, cells were infected with VSV-GFP for 12 h. The replication of VSV-GFP was detected via fluorescence microscopy. Data are representative of three independent experiments. \*\*\*, *p* \<  0.001; \*\*, *p* \<  0.01; ns, not significant. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)Fig. 1

3.2. PDCoV nsp15 inhibits SEV-induced activation of NF-κB {#sec0065}
---------------------------------------------------------

It is well known that the interferon regulatory factor 3 (IRF3) and NF-κB are critical transcription factors for induction of type I IFN ([@bib0200]). Since the above results indicate that PDCoV nsp15 is an IFN-β antagonist, we thus next investigated if PDCoV nsp15 affects the SEV-induced activation of IRF3 and NF-κB. LLC-PK1 or HEK-293T cells were co-transfected with pCAGGS-HA-nsp15 and the IRF3-Luc or NF-κB-Luc luciferase reporter plasmid together with pRL-TK, after which they were infected with SEV for 12 h. The results of luciferase reporter assays showed that PDCoV nsp15 blocked the SEV-induced promoter activity of NF-κB in a dose-dependent manner in both LLC-PK1 ([Fig. 2](#fig0010){ref-type="fig"} **A**) and HEK-293T cells ([Fig. 2](#fig0010){ref-type="fig"} **B**), but it had no effect on the SEV-induced promoter activity of IRF3 in both LLC-PK1 ([Fig. 2](#fig0010){ref-type="fig"} **C**) and HEK-293T cells ([Fig. 2](#fig0010){ref-type="fig"} **D**).Fig. 2PDCoV nsp15 impairs SEV-induced activation of NF-κB. (**A**--**D**) LLC-PK1 cells (A, C) or HEK-293T cells (B, D) grown in 24-well plates were co-transfected with NF-κB-Luc (A, B) or IRF3-Luc (C, D) and pRL-TK together with increasing quantities (0.1, 0.5, and 1.0 μg) of PDCoV nsp15 expression plasmid for 24 h, followed by infection with SEV or mock-infection for 12 h before luciferase reporter assays were performed. The averages of data from three independent experiments are shown. \*\*\*, *p* \<  0.001. (**E**, **F**) LLC-PK1 cells (E) or HEK-293T cells (F) cultured in 60-mm dishes were mock-transfected or transfected with increasing amounts (3, 5, and 7 μg) of pCAGGS-HA-nsp15 for 24 h before infection or mock-infection with SEV for 8 h. Western blot analyses with antibodies against p-IRF3 (Ser386), IRF3, p-p65 (Ser536), p65, HA, or β-actin were performed on lysates from these cells. The relative levels of rate of p-p65 /p65 in comparison to the control group are shown as fold values below the images via Image J software analysis. (**G**, **H**) LLC-PK1 cells (G) or HEK-293T cells (H) cultured in 24-well plates were transfected with 1.0 μg of pCAGGS-HA-nsp15, followed by SEV infection for 6 h, and subjected to indirect immunofluorescence assays to detect endogenous p65 (green) and PDCoV nsp15 (red) with rabbit anti-p65, and mouse anti-HA antibodies, respectively. The cell nuclei (blue) were stained with DAPI. Fluorescent images were acquired with a confocal laser scanning microscope (Fluoviewver. 3.1; Olympus, Japan). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)Fig. 2

The phosphorylation and nuclear translocation of IRF3 and the NF-κB p65 subunit are the hallmarks for activation of IRF3 and NF-κB, respectively, so we next investigated the effects of PDCoV nsp15 on the phosphorylation and nuclear translocation of IRF3 and p65. To this end, LLC-PK1 or HEK-293T cells were transfected with pCAGGS-HA-nsp15 or empty vector, followed by SEV infection. Western blot assays were performed on lysates of these cells to analyze the phosphorylation levels of IRF3 and p65. As shown in [Fig. 2](#fig0010){ref-type="fig"} **E** and **F**, the phosphorylation levels of endogenous IRF3 and p65 were both markedly higher following SEV infection, compared with the levels in mock-infected cells. In line with our previous results from luciferase reporter assays, the SEV-induced p65 phosphorylation in nsp15-expressing cells was notably inhibited, but nsp15 failed to impede the IRF3 phosphorylation induced by SEV in both LLC-PK1 ([Fig. 2](#fig0010){ref-type="fig"} **E**) and HEK-293T cells ([Fig. 2](#fig0010){ref-type="fig"} **F**). The results of nuclear translocation assays of IRF3 and p65 also showed that nsp15 expression inhibited the SEV-induced nuclear translocation of p65 in both LLC-PK1 ([Fig. 2](#fig0010){ref-type="fig"} **G**) and HEK-293T cells ([Fig. 2](#fig0010){ref-type="fig"} **H**), but not that of IRF3 in both cell lines (data not shown). Overall, these results demonstrate that PDCoV nsp15 antagonizes SEV-induced IFN-β production mainly by inhibiting the activation of NF-κB.

3.3. PDCoV nsp15 inhibits IFN-β production independently of its endoribonuclease activity {#sec0070}
-----------------------------------------------------------------------------------------

Previous study has demonstrated that PDCoV nsp15 His219 (H219), H234, and Lys269 (K269) are the critical sites for its endoribonuclease activity ([@bib0230]). To investigate whether or not PDCoV nsp15 mutants lacking endoribonuclease activity possess the ability to antagonize IFN-β production. LLC-PK1 cells were co-transfected with expression plasmids encoding PDCoV WT nsp15 or one of its mutants (H219A, H234A, or K269A), together with IFN-β-Luc and pRL-TK, followed by stimulation with SEV. The results of dual-luciferase reporter assays showed that all three mutants significantly inhibited the SEV-induced IFN-β promoter activity, similar to the WT nsp15. ([Fig. 3](#fig0015){ref-type="fig"} **A**). We also used HEK-293T cells to repeat the experiments and similar results were observed ([Fig. 3](#fig0015){ref-type="fig"} **B**). Based on these results, we can conclude that the endoribonuclease activity of PDCoV nsp15 is not essential for inhibiting IFN-β production.Fig. 3PDCoV nsp15 inhibits IFN-β production independently of its endoribonuclease activity. LLC-PK1 cells (**A**) or HEK-293T cells (**B**) cultured in 24-well plates were transfected with 1.0 μg of expression plasmid (PDCoV nsp15, H219A, H234A, or K269A) or empty vector, along with IFN-β-Luc and pRL-TK for 24 h. The cells were then mock-infected or infected with SEV for 12 h and subjected to dual-luciferase reporter assays. Data are means ± SD from three independent experiments. \*\*\*, *p* \<  0.001; \*\*, *p* \<  0.01; \*, *p* \<  0.05.Fig. 3

3.4. The mutants of PDCoV nsp15 lacking endoribonuclease activity significantly inhibit SEV-induced NF-κB activation {#sec0075}
--------------------------------------------------------------------------------------------------------------------

Because PDCoV nsp15 mutants lacking endoribonuclease activity can still antagonize IFN-β production, we further investigated if, similar to the WT nsp15, the nsp15 mutants could also impair NF-κB activation. To this end, LLC-PK1 or HEK-293T cells were co-transfected with expression plasmids encoding one of the nsp15 mutants (H219A, H234A, or K269A) and the NF-κB-Luc luciferase reporter plasmid, together with the internal control plasmid pRL-TK, and then infected with SEV. A plasmid encoding the WT nsp15 was used as a control. The results of dual-luciferase reporter assays revealed that all mutants of PDCoV nsp15 suppressed the SEV-induced promoter activity of NF-κB to a similar degree as the WT nsp15 in both LLC-PK1 ([Fig. 4](#fig0020){ref-type="fig"} **A**) and HEK-293T cells ([Fig. 4](#fig0020){ref-type="fig"} **B**). We also analyzed the phosphorylation levels of endogenous IRF3 and p65 after the overexpression of nsp15 mutants in both LLC-PK1 ([Fig. 4](#fig0020){ref-type="fig"} **C**) and HEK-293T ([Fig. 4](#fig0020){ref-type="fig"} **D**) cells, and the results demonstrated that cells transfected with any of the three mutants, similar to the WT nsp15, markedly decreased p65 phosphorylation compared to the cells transfected with empty vector, while the expression levels of total IRF3 and p65 and the phosphorylation level of IRF3 were similar among all groups ([Fig. 4](#fig0020){ref-type="fig"} **C** and **D**). Using the mutant H234A as a representative, we analyzed the nuclear translocation of endogenous IRF3 and p65 after the overexpression of a nsp15 mutant. Similar to the WT nsp15, when the mutant H234A was ectopically expressed, it also inhibited the SEV-induced nuclear translocation of p65 in both LLC-PK1 ([Fig. 4](#fig0020){ref-type="fig"} **E**) and HEK-293T cells ([Fig. 4](#fig0020){ref-type="fig"} **F**), but did not affect IRF3 translocation in both cell lines (data not shown). Together, our results suggest that the nsp15 mutants lacking endoribonuclease activity utilized a similar mechanism as the WT nsp15 to antagonize IFN-β production by impairing NF-κB activation.Fig. 4PDCoV nsp15 mutants lacking endoribonuclease activity also significantly inhibit SEV-induced activation of NF-κB. (**A**, **B**) LLC-PK1 cells (A) or HEK-293T cells (B) grown in 24-well plates were co-transfected with NF-κB--Luc together with pRL-TK and 1.0 μg of expression plasmid (PDCoV nsp15, H219A, H234A, K269A) or empty vector for 24 h, followed by stimulation with SEV for 12 h before luciferase reporter assays were performed. \*\*\*, *p* \<  0.001; \*, *p* \<  0.05; ns, not significant. (**C**, **D**) LLC-PK1 cells (C) or HEK-293T cells (D) were transfected with expression plasmid (PDCoV nsp15, H219A, H234A, K269A) or empty vector and infected with SEV, and cells were then collected for western blot analyses using antibodies against p-IRF3, IRF3, p-p65, p65, HA, and β-actin. (**E**, **F**) Nsp15 H234A acts as a representative mutant protein to analyze its effect on nuclear translocation of p65. LLC-PK1 cells (E) or HEK-293T cells (F) were transfected with PDCoV nsp15 or H234A expression plasmid and then infected with SEV. Immunofluorescence analyses to detect endogenous p65 (green) and PDCoV nsp15/H234A (red) were performed with rabbit anti-p65, and mouse anti-HA antibodies, respectively. The nuclei (blue) were stained with DAPI. Cells transfected with an empty vector or mock-infected with SEV were used as negative controls. Fluorescent images were acquired with a confocal laser scanning microscope (Fluoviewver. 3.1; Olympus, Japan). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)Fig. 4

4. Discussion {#sec0080}
=============

To combat the antiviral effects of IFN, many viruses have evolved elaborate strategies to inhibit IFN production. For PDCoV, previous studies have revealed that PDCoV infection suppresses the RIG-I-mediated production of type I IFN ([@bib0110]). To date, nsp5 and accessory protein NS6 encoded by PDCoV have been confirmed to be antagonists IFN production ([@bib0235]; [@bib0050]). Whether other proteins from PDCoV have also been responsible for the inhibition of RIG-I-mediated production of IFN-β remains to be unclear. To further identify and characterize the PDCoV-encoded IFN antagonists will broaden our understanding of its infection and pathogenesis.

As a unique endoribonuclease encoded by nidoviruses, the functions of nsp15 of CoVs (nsp11 in arteriviruses) have been received more attentions. Previous studies showed that the nsp15 encoded by SARS-CoV ([@bib0055]), MHV ([@bib0020]), PEDV ([@bib0225]; [@bib0025]) and the nsp11 encoded by PRRSV ([@bib0145]; [@bib0165]) can antagonize antiviral innate immune responses. Our present study also found that the nsp15 of PDCoV antagonizes type I IFN production, suggesting that it may be a common property for the endoribonuclease of nidoviruses to antagonizes IFN production. However, it is appears that different mechanisms are utilized by the endoribonucleases from different nidoviruses. For example, the nsp15 s of MHV and HCoV-229E prevent the activation of IFN response by mediating the evasion of host recognition of viral dsRNA ([@bib0020]; [@bib0090]); PRRSV nsp11, the orthologue of CoV nsp15, antagonizes type I IFN production by suppressing both MAVS and RIG-I expression ([@bib0165]). SARS-CoV nsp15 antagonizes type I IFN production by inhibiting MAVS-induced apoptosis ([@bib0100]), however, MERS-CoV nsp15 does not utilize this strategy although it also inhibits type I IFN production with a yet-to-be identified mechanism. More recently, PEDV nsp15 has been demonstrated to be involved in IFN antagonize through a possible mechanism similar to the nsp15 of MHV and HCoV-229E ([@bib0025]). Although different mechanisms are utilized by the endoribonucleases from different nidoviruses, it appears that all tested endoribonucleases inhibit the activations of both IRF3 and NF-κB, the two critical transcription factors for induction of type I IFN production. In this study, we found that PDCoV nsp15 antagonizes IFN-β production by impairing the activation of transcription factor NF-κB, but not IRF3, which is a different strategy from other reported endoribonucleases of nidoviruses.

Although all tested endoribonuclease of nidoviruses have been demonstrated to antagonize IFN production, it is still inconclusive whether this function fully depends on its endoribonuclease activity. Several studies showed that overexpression of WT nsp15 s of CoV or nsp11 s of arterivirus significantly suppressed IFN production, while the mutants lacking endoribonuclease activity lost this capacity ([@bib0090]; [@bib0145]; [@bib0165]). These evidences appear to indicate that the endoribonuclease activity is essential for nsp15/nsp11-mediated inhibition of IFN production. However, the WT nsp15 s or nsp11 s have been demonstrated to be extremely toxic to prokaryotic and eukaryotic cells, on the contrary, no cytotoxicity could be observed in cells overexpressing nsp15/nsp11 mutants lacking endoribonuclease activity ([@bib0015]; [@bib0165]). Thus, many researchers suspected that the suppression of IFN production by WT nsp15/nsp11 is due to its cytotoxicity ([@bib0015]; [@bib0150]). In addition, although MHV A59 mutant expressing a catalysis-deficient nsp15 induces robust type I IFN production compared to wild-type MHV in the infected macrophages, however, another mutant expressing an unstable nsp15 also exhibits similar property ([@bib0020]). Thus, no direct evidence for the linkage between endoribonuclease activity and type I IFN antagonism has been obtained. In this study, we found that PDCoV nsp15 antagonizes IFN production independent on its endoribonuclease activity. Both WT nsp15 and its mutants lacking endoribonuclease activity inhibited type I IFN production to a similar degree. These results indicated that PDCoV nsp15 has evolved a novel mechanism for the antagonism of IFN production in an endoribonuclease activity-independent manner, distinct from that reported previously for the inhibition of IFN-β production by other CoV nsp15 s or arterivirus nsp11 s. The reason that results in these differences remains unclear. In terms of structure, the active form of endoribonuclease from PDCoV nsp15 is different from that of other CoV nsp15 s. PDCoV nsp15 is a mixture of dimers and monomers, while the nsp15 s of SARS-CoV, MHV, HCoV-229E, as well as MERS-CoV, function as a hexamer ([@bib0135]; [@bib0210]; [@bib0220]; [@bib0230]). Whether these structure differences result in different mechanisms used to antagonize IFN production remains further study. In addition, it should be noted that this study involved the individual expression of PDCoV nsp15, outside the context of infection. However, we also compared the inhibitory effects of PEDV WT nsp15 and its mutant (nsp15 H226A) lacking endoribonuclease activity in overexpression system, and found that the PEDV WT nsp15 significantly inhibited IFN-β production, while such an inhibitory effect was not observed in cells overexpressing mutant nsp15 H226A (data not shown). Because the reverse genetics system of PDCoV is not available nowadays, it is difficult to investigate the IFN antagonist activity of PDCoV nsp15 in the context of virus infection. We are now working to establish a reverse genetics system of PDCoV, which will allow the generation of mutant or deletion viruses to investigate the precise mechanism of PDCoV nsp15-mediated inhibition of type I IFN.

In summary, our present study reveals that PDCoV nsp15 acts an IFN antagonist. Distinct from the endoribonucleases of other nidoviruses, PDCoV nsp15 impairs NF-κB activation rather than IRF3 activation. Furthermore, PDCoV nsp15 inhibits type I IFN production independent its endoribonuclease activity. These results indicated that PDCoV nsp15 may utilizes a distinct mechanism to antagonize type I IFN production.
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